Our discovery platform enables us to develop best-in-class therapeutic antibodies in auto-immune and inflammatory disease.
Monoclonal antibodies have proven to be efficacious in several inflammatory and immune diseases, including rheumatoid arthritis, inflammatory bowel disease and psoriasis, commonly targeting cytokines, receptors, and other signalling molecules.
We are determined to exploit the strength of our antibody discovery platform to deliver a new generation of therapeutic antibodies that tackle inflammatory disorders, which continue to represent a high level of unmet clinical need.
Among our projects are lead antibody therapeutics against OX40L, which is expressed on antigen-presenting cells and activates T-cells through binding its receptor OX40. We are developing this product for T-cell driven inflammatory diseases. This molecule will enter the clinic in 2017.